Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg D
Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock
10:16am, Monday, 11'th Aug 2025
Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript
10:20pm, Thursday, 07'th Aug 2025
Insmed Incorporated (NASDAQ:INSM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Bryan Dunn - Vice President of Investor Relations Martina Flammer - Chief Medical Off
Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 07'th Aug 2025
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
09:21am, Thursday, 07'th Aug 2025
Insmed (INSM) came out with a quarterly loss of $1.7 per share versus the Zacks Consensus Estimate of a loss of $1.3. This compares to a loss of $1.94 per share a year ago.
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 07'th Aug 2025
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib
Insmed (INSM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:15am, Tuesday, 05'th Aug 2025
Beyond analysts' top-and-bottom-line estimates for Insmed (INSM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
11:08am, Thursday, 31'st Jul 2025
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
07:00am, Thursday, 24'th Jul 2025
BRIDGEWATER, N.J. , July 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
It is time for a move higher in biotech, says Mizuho's Jared Holz
06:29pm, Monday, 07'th Jul 2025
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
Russell Rebalance: 3 Stocks Ready to Move Higher
07:08am, Friday, 20'th Jun 2025
Investors pay close attention to the quarterly rebalancing of the S&P 500 index for good reason. First, the stocks in the S&P 500 make up approximately 80% of the total U.S. equity market.
Is Insmed Stock Overvalued After The 45% Jump?
05:05am, Monday, 16'th Jun 2025
Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
10:25pm, Wednesday, 11'th Jun 2025
BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Insmed Announces Proposed $650 Million Public Offering of Common Stock
04:01pm, Wednesday, 11'th Jun 2025
BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock
01:36pm, Wednesday, 11'th Jun 2025
United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Insmed's treprostinil based product seemingly edged United's Tyvaso on key measu
